The potential link between hypomagnesemia and glucose intolerance, especially in the context of diabetes mellitus, warrants further investigation. SGLT2 inhibitors, established for their role in diabetes management, are associated with a significant increase in serum magnesium concentration among diabetic patients [2]. This evidence concerns the gene SLC5A2 and familial primary hypomagnesemia.